Antiviral therapy for COVID-2019

• المؤلفون الرئيسيون: Hanik Badriyah Hidayati, -, Evi Octavia, -, Cempaka Thursina Srisetyaningrum, -
• التنسيق: مقال PeerReviewed
• اللغة: English; English; English; English
• منشور في: Faculty of Anaesthesia, AFMS 2021
• الموضوعات: R Medicine (General); RC Internal medicine
• الوصول للمادة أونلاين: https://repository.unair.ac.id/117645/1/C-3%20Peer%20Review.pdf; https://repository.unair.ac.id/117645/2/C-3%20Turnitin.pdf; https://repository.unair.ac.id/117645/3/C-3%20Artikel.pdf; https://repository.unair.ac.id/117645/4/C-3%20Bukti%20Koresponding.pdf; https://repository.unair.ac.id/117645/; https://www.apicareonline.com/index.php/APIC/article/view/1522; https://doi.org/10.35975/apic.v25i3.1522

The whole world is experiencing a global pandemic caused by Coronavirus disease 2019. As the pandemic progresses, there has been much research on antiviral drugs, such as hydroxychloroquin, chloroquine, remdesivir, lopinavir-ritonavir, favipiravir, oseltamivir, and umifenovir. Specific antiviral dr...